Keywords: neurocrine, indiplon, profile, backed, ph, iii, biosciences

Neurocrine's indiplon profile backed in Ph III

Article | 26 May 2003

Print This

Neurocrine Biosciences of the USA has reported promising Phase III data on its novel hypnotic drug indiplon which suggest that ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in